SEP 10, 2026 · PHASE 1 TRIAL
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
ClinicalTrials.gov
Phase 1 trial of a novel MAPK pathway inhibitor in advanced solid tumors; registry record with no results posted, only planned endpoints for safety, dosing, and antitumor activity assessment.
Reported
Planned enrollment98
Study phasePhase 1
Primary outcome (Part A)Number of Participants With Dose-Limiting T…